Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330996 | 1.00 | KISS1R (0.51) | KISS1ROPRD1OPRK1OPRM1NTSR2 | |
| SCHEMBL23331150 | 0.98 | KISS1R (0.49) | KISS1ROPRD1OPRK1OPRM1CTSD | |
| SCHEMBL23331575 | 0.97 | KISS1R (0.48) | KISS1ROPRD1OPRK1OPRM1NTSR2 | |
| SCHEMBL23331567 | 0.95 | CTSD (0.50) | KISS1ROPRK1CTSDBACE1 | |
| SCHEMBL23331151 | 0.94 | KISS1R (0.51) | KISS1ROPRD1OPRK1OPRM1BACE1 | |
| SCHEMBL24519284 | 0.90 | KISS1R (0.55) | KISS1ROPRK1REN | |
| SCHEMBL23330898 | 0.90 | OPRD1 (0.52) | KISS1ROPRD1OPRK1OPRM1 | |
| SCHEMBL23331377 | 0.88 | KISS1R (0.57) | KISS1ROPRD1OPRK1OPRM1CTSD | |
| SCHEMBL23331247 | 0.88 | KISS1R (0.55) | KISS1ROPRK1REN | |
| SCHEMBL23331572 | 0.85 | CTSD (0.55) | KISS1RCTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | BIOVENTURES, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210128669-A1 | LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USING THE SAME | BIOVENTURES, LLC (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | NGLY1, VIP, CLPTM1 | KISS1R 1143/4885OPRD1 3528/4885OPRK1 3994/4885 |
| US-20210128669-A1 | LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USING THE SAME | NGLY1, VIP, CLPTM1 | KISS1R 1143/4885OPRD1 3528/4885OPRK1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.